NoThIngVesting

Here to keep tabs on the chaos, one move at a time. Invested in Stocks, Media, Tech & AI

[NoThIngVesting @longtermchair]

$NTLA March 10, 2027

[Intellia Therapeutics @intelliatx]

📢 $NTLA News: And so the countdown begins... We are proud to share the @US_FDA has accepted Intellia's Biologics License Application (BLA) with Priority Review for our potential one-time #hereditaryangioedema treatment. The PDUFA target action date is March 10, 2027.

Read the full announcement: https://t.co/fJP8TEqIRm

[NoThIngVesting @longtermchair]

The offering was upsized to $550 million. Due March 2031. $76.56 represents a premium of approximately 45%. $CRSP

[NoThIngVesting @longtermchair]

$NTLA Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

[NoThIngVesting @longtermchair]

aaaaand we're back $NTLA

[NoThIngVesting @longtermchair]

bad news for $NTLA

[NoThIngVesting @longtermchair]

$CRSP Good news!
https://t.co/f82rIqLtRq

[NoThIngVesting @longtermchair]

@GeneInvesting $40 for April seems doable don't you think?

[NoThIngVesting @longtermchair]

CRISPR Therapeutics announces $600M at-the-market share offering to boost cash reserves $CRSP

[NoThIngVesting @longtermchair]

Biotech portfolio up 65%, reaching its highest close so far. Positioned with 45% $CRSP, 28% $NTLA, and a 26% cash buffer.

[NoThIngVesting @longtermchair]

Patience, everything is easier than it looks.

[NoThIngVesting @longtermchair]

so... we're back

[NoThIngVesting @longtermchair]

@GeneInvesting wtf. selling at 52w low is not very smart sir. everyone has their case but, selling a looser to add to another one does not sound right

[NoThIngVesting @longtermchair]

unexpected.
if it stays at these levels I will be averaging down.
holding lil bit of cash for now.

[NoThIngVesting @longtermchair]

Great news.
Buying opportunity.
Market cap of $850M at 52w lows.
Averaging down if it goes to $7.35 $NTLA

[Intellia Therapeutics @intelliatx]

$NTLA News: @US_FDA grants Intellia Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z) for the treatment of #ATTR #amyloidosis with cardiomyopathy. https://t.co/YnslygkjBI

[NoThIngVesting @longtermchair]

https://t.co/VDuKYXyHW6

[NoThIngVesting @longtermchair]

Sen. Scott meets with Trump NIH Nominee, Bhattacharya $CRSP

“Enjoyed sitting down with Dr. Bhattacharya to discuss life expectancy, sickle cell disease gene therapies like using CRISPR, the fight to cure cancer...”

[NoThIngVesting @longtermchair]

@GeneInvesting you should hop on the next ER call and ask. you’re on top of your game. thanks

[NoThIngVesting @longtermchair]

$CRSP Why Cures Command 20x the Value of Traditional Treatments https://t.co/LVuJzjsLxn

[NoThIngVesting @longtermchair]

$300B Pharma Revenue at Risk—Will Cures Fill the Gap? $CRSP $NTLA $PRME

[NoThIngVesting @longtermchair]

@GeneInvesting @TheValueGame @RLCscienceboss @endpts may I ask why you sold out of CRSP?